Carbapenemase-producing bacteria in Europe
This report summarises the results of a survey to gather information about the spread of carbapenemase-producing Enterobacteriaceae and carbapenems-resistant Acinetobacter baumannii in Europe.
Rapid risk assessment: Carbapenem-resistant Enterobacteriaceae, 14 April 2016
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
Rapid Risk Assessment: Plasmid-mediated colistin resistance in Enterobacteriaceae, 15 June 2016
This document assesses the risk for patients and healthcare systems in the EU/EEA due to the global mcr-1 plasmid-mediated gene epidemic.
ECDC study protocol for genomic-based surveillance of carbapenem-resistant and/or colistin-resistant Enterobacteriaceae at the EU level
This ECDC study protocol describes the technical requirements for implementing future EU-level genomic-based surveillance of carbapenem-resistant and/or colistin-resistant Enterobacteriaceae.
US CDC guidance for control of carbapenem-resistant Enterobacteriaceae (CRE) – 2012 CRE toolkitArchived
Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are highly resistant to antibiotics, leaving only a few options for treatment of infected patients, and thus represent a serious threat to public health.
US CDC report on antibiotic resistance threats in the United States, 2013
Antimicrobial resistance represent a serious threat to public health and patient safety and is a worldwide problem. Each year, in the European Union (EU) at least 25 000 patients die of infections with multidrug-resistant bacteria.
Cross-border transfer increases patients’ risk of resistant bacteriaArchived
Patient transfer between hospitals and in particular between countries, is a risk factor for the spread of bacteria that are resistant to last-line antibiotics. More specifically, for highly resistant bacteria, like carbapenamase-producing Enterobacteriaceae (CPE), the risk is heightened when patients are transferred from, or have received previous medical care in areas with high rates of bacterial resistance. These are conclusions from a risk assessment produced by ECDC that evaluated the risk to the citizens of Europe, of the spread of CPE through patient transfer between healthcare facilities, with special emphasis on cross-border transfer.
New Delhi metallo-beta-lactamase 1-producing Enterobacteriaceae: Emergence and response in Europe
Struelens, M.J., Monnet, D.L., Magiorakos, A.P., O'Connor, F.S., Giesecke, J.
Antimicrobial resistance 2010: Global attention on carbapenemase-producing bacteria
Monnet, D.L., Suetens, C., Earnshaw, S., Gagliotti, C., Griskeviciene, J., Heuer, O.E., Khazeeva, E., Kleinkauf, N., Liljestedt, E., Magiorakos, A.-P., Santos, F., Struelens, M.J., Weber, J.T., Weist, K.
Carbapenemase-producing Enterobacteriaceae in Europe: A survey among national experts from 39 countries, February 2013
Glasner, C., Albiger, B., Buist, G., Tambić, A.A., Canton, R., Carmeli, Y., Friedrich, A.W., Giske, C.G., Glupczynski, Y., Gniadkowski, M., Livermore, D.M., Nordmann, P., Poirel, L., Rossolini, G.M., Seifert, H., Vatopoulos, A., Walsh, T., Woodford, N., Donker, T., Monnet, D.L., Grundmann, H.